TrialEsophagus : official journal of the Japan Esophageal Society2026

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up.

Takashi Ogata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.